Casandra
Casandra Test Code QD13280Version 1 (DRAFT)
Performing Lab
DCP (Des‑gamma‑Carboxy Prothrombin)
Also known as: PIVKA-II
Clinical Use
Order TestUse
The DCP assay is intended for in vitro diagnostic use as an aid in the risk assessment of patients with chronic liver disease for progression to hepatocellular carcinoma (HCC), in conjunction with other laboratory findings and clinical assessment.
Special Instructions
Not provided.
Limitations
Not provided.
Test Details
Methodology
Immunoassay (IA)
Biomarkers
Des‑gamma‑Carboxy Prothrombin
AnalyteQuantitation • Concentration / Level • Quantitative (Continuous) (e.g., copies/mL, % expression)
Result Turnaround Time
2-3 days
Related Documents
For more information, please review the documents below
Specimen Requirements
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Red Top (No Additive)
Causes for Rejection
Hemolysis; Lipemia; Heavy, visible particulate matter
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 48 Hours |
| Refrigerated | 7 Days |
| Frozen | 21 Days |
Related Tests
Other tests from different labs that may be relevant
Des-γ-carboxy Prothrombin (DCP)
Labcorp
Des-gamma-carboxy Prothrombin
ARUP Laboratories
Des-Gamma-Carboxy Prothrombin, Serum
Mayo Clinic Lab
Hepatocellular Carcinoma Tumor Marker Panel
ARUP Laboratories
Probability of Hepatocellular Carcinoma, Serum
Mayo Clinic Lab
Hepatocellular Carcinoma Risk Panel with GALAD Score, Serum
Mayo Clinic Lab
GALAD Score, Serum
Mayo Clinic Lab
α-Fetoprotein (AFP) With AFP-L3%
Labcorp
Hepatitis D Virus (HDV) Antibody, IgG and IgM
Labcorp
Hepatitis Delta Virus by Quantitative PCR
ARUP Laboratories